Median OS 9.9 m 5-year OS 16% (43% for PDL‐1 ≥ 50%) For 5-year survivors: 14/16 current or former smokers, 10/16 had received prior RT, 12/16 no further tx after stopping Nivo and without PD in 7, ≥50% in 5, <1% in 3 pts
101 tx naïve 449 previously treated Median follow-up: 60.6 m
Treatment naïve: Median DOR 16.8 m; CR 3% (3 patients) Median OS 22.3 m 5-year OS 23.2% (29.6% for ) Previously treated: Median DOR 38.9 m; CR 1.1% (5 patients) Median OS 10.5 m (15.5 m for ) 5-year OS 15.6% (25% for )
Median DOR: 22.3 m (vs. 7.2 m docetaxel) 3-year OS: ITT 16.6% (vs. 10% docetaxel) IHC TC3 or IC3 37.5% (vs. 14.9%) IHC TC 2/3 or IC 2/3 21.2% (vs. 9.9%)
47 male; adenocarcinoma Current smoker SBRT to LNs while on Nivo
PR after 6 cycles; CR after 13 cycles (10 weeks after RT) Nivo discontinued after cycle 17 due to pancreatitis; still in CR almost 2 years since discontinuation
Abbreviations: OS—overall survival; m—months; tx—treatment; DOR—duration of response; CR—complete response; PD—progressive disease; ITT—intention to treat; Nivo—nivolumab; doc—docetaxel; LN—lymph node; ca—carcinoma; NSCLC—non-small-cell lung cancer; RT—radiotherapy; SBRT—stereotactic body radiation therapy; IHC—immunohistochemistry; TC—tumor cells; IC—tumor-infiltrating immune cells; Mut/Mb—mutations per megabase; PDL-1—programmed death ligand-1.